| PATENT ASSIGNEE'S COUNTRY | USA |
| UPDATE | 09.99 |
| PATENT ASSIGNEE | Washington University |
| PATENT CLAIMS |
- Adm to patient who does not yet display clinically detecta ble symptoms of Alzheimer's disease, but who has been diagnosed as having a presymptomatic disposition toward Alzheimer's disease, a drug regimen which includes an NMDA antagonist drug which penetrates mammalian blood-brain barriers & which has an inherent safener activi ty that prevents the NMDA antagonist drug from inflicting neu rotoxic side effects inside the patient's brain, at a therapeuti cally effective dosage which prevents excessive excitation of NMDA receptors - Periodically evaluating the patient to determine whether the patient displays clinically detectable symptoms of Alzheimer's disease, so that adm of the NMDA antagonist drug can be terminated if clinically detectable symptoms of the disease are manifested by patient |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |